GlassScriptPhysician profile
Shawna M Mason
NPI 1194794370
$4,649.50
in general payments reported to CMS, 2019-2025
34 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $983 · 2022: $875 · 2023: $710 · 2024: $979 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,021.51 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $490.58 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Scpharmaceuticals INC. | $453.95 | 2025 | |
| Abbvie INC. | $372.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.50 | 2021-2025 | Wainua, Airsupra |
| Janssen Pharmaceuticals, INC | $222.94 | 2021-2022 | |
| Amgen INC. | $220.59 | 2021-2025 | Evenity, Prolia, Prolia |
| Nevro Corp. | $145.86 | 2021-2023 | Senza |
| Astellas Pharma US INC | $116.34 | 2021-2023 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $115.26 | 2024 | Camzyos |
| Otsuka America Pharmaceutical, INC. | $113.48 | 2023 | Rexulti, Nuedexta |
| Abbott Laboratories | $109.50 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $101.12 | 2021-2022 | |
| Corium, LLC | $91.70 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.20 | 2021-2024 | Jardiance, Ofev, Tradjenta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $72.21 | 2021-2022 | |
| Pfizer INC. | $67.15 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.78 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.15 | 2025 | Lifevest |
| Medtronic, INC. | $59.46 | 2025 | Symplicity G3 |
| Phathom Pharmaceuticals, INC. | $52.94 | 2024-2025 | Voquezna |
| Dexcom, INC. | $44.13 | 2024-2025 | Dexcom G6 Transmitter |
| Alpha Cognition USA, INC. | $38.43 | 2025 | Zunveyl |
| Biohaven Pharmaceutical Holding Company LTD. | $36.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.80 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $26.82 | 2022-2023 | Dificid |
| Scilex Pharmaceuticals INC. | $23.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.28 | 2021 | |
| Corcept Therapeutics | $17.12 | 2023 | Korlym |
| Eisai INC. | $16.03 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2022 | |
| Horizon Therapeutics Plc | $13.38 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.65 | 2022 | |
| Lilly USA, LLC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawna Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.